Mendez-Enriquez E, García-Zepeda E A
Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Circuito Escolar S/N, Ciudad Universitaria, 04510, México, DF, México.
Inflammopharmacology. 2013 Dec;21(6):397-406. doi: 10.1007/s10787-013-0177-5. Epub 2013 Jul 12.
CCL13/MCP-4, is a CC family chemokine that is chemoattractant for eosinophils, basophils, monocytes, macrophages, immature dendritic cells, and T cells, and its capable of inducing crucial immuno-modulatory responses through its effects on epithelial, muscular and endothelial cells. Similar to other CC chemokines, CCL13 binds to several chemokine receptors (CCR1, CCR2 and CCR3), allowing it to elicit different effects on its target cells. A number of studies have shown that CCL13 is involved in many chronic inflammatory diseases, in which it functions as a pivotal molecule involved in the selective recruitment of cell lineages to the inflamed tissues and their subsequent activation. Based on these studies, we suggest that blocking the actions of CCL13 can serve as a novel strategy for the generation of agents with anti-inflammatory activity. The main goal of this review is to present the current information about CCL13, its gene and protein structure and the roles of this chemokine during innate/adaptive immune responses in inflammatory diseases.
CCL13/MCP - 4是一种CC族趋化因子,对嗜酸性粒细胞、嗜碱性粒细胞、单核细胞、巨噬细胞、未成熟树突状细胞和T细胞具有趋化作用,并且能够通过对上皮细胞、肌肉细胞和内皮细胞的作用诱导关键的免疫调节反应。与其他CC趋化因子类似,CCL13与多种趋化因子受体(CCR1、CCR2和CCR3)结合,使其能够对其靶细胞产生不同的作用。多项研究表明,CCL13参与许多慢性炎症性疾病,在这些疾病中,它作为一个关键分子参与细胞谱系向炎症组织的选择性募集及其随后的激活。基于这些研究,我们认为阻断CCL13的作用可作为产生具有抗炎活性药物的一种新策略。本综述的主要目的是介绍有关CCL13、其基因和蛋白质结构以及这种趋化因子在炎症性疾病的固有/适应性免疫反应中的作用的当前信息。